长双歧杆菌NCC2705株果糖结合蛋白BL0033基因的克隆及其在大肠杆菌中的表达

目的：克隆长双歧杆菌NCC2705株果糖结合蛋白BL0033的基因,利用大肠杆菌表达GST-BL0033融合蛋白并纯化。方法：以长双歧杆菌NCC2705株基因组为模板,PCR扩增BL0033基因,并将其插入pGEX-4T-1表达载体,转化至大肠杆菌DH5α;提取质粒,经PCR、质粒双酶切及测序鉴定后,转入大肠杆菌BL21,并对表达条件进行摸索;用谷胱甘肽-Sepharose4B树脂对可溶性GST-BL0033融合蛋白进行纯化。结果：PCR扩增的BL0033基因长度接近1000bp,与预期值一致;重组菌在IPTG浓度为0.05mmoL/L的条件下,于16℃诱导过夜后,SDS-PAGE分析可见可溶性表达条带,相对分子质量约60×103,与预期值一致;亲和纯化后,SDS-PAGE结果显示单一的表达条带。结论：克隆了BL0033蛋白的基因,并表达纯化了融合蛋白GST-BL0033,为进一步研究长双歧杆菌NCC2705株BL0033蛋白功能奠定了基础。     

CD／5-FC自杀基因治疗系统对恶性人脑胶质瘤细胞影响的离体研究

在离体条件下探讨CD/5 FC自杀基因治疗系统对恶性人脑胶质瘤细胞的抗癌作用。通过将CD基因插入真核表达载体pcDNA3.0多克隆位点构建pCMVCD表达质粒 ,采用限制性内切酶消化鉴定所构建的质粒 ,并进行CD基因测序。采用LipofectAMINE2 0 0 0脂质体介导法将CD基因转染U2 5 1恶性人脑胶质瘤细胞 ,G4 18筛选获得抗性克隆 (取名为U2 5 1/CD细胞 ) ,使用不同浓度的 5 FC作用于U2 5 1/CD细胞 ,MTT法测定活性细胞比率。采用高效液相色谱法 (HPLC)检测 5 FC培养液内 5 FU的浓度。结果如下 :真核表达质粒pCMVCD构建成功 ,并通过酶切鉴定。U2 5 1细胞获得了质粒的成功转染。未转染的U2 5 1细胞对 5 FC不敏感 ,IC50 约为 6 5 0 0 μmol/L ,而转染基因后IC50 约为 10 μmol/L。基因转染使G4 18抗性细胞(U2 5 1/CD细胞 )对 5 FC高度敏感。并且加入不同浓度的 5 FC后 ,U2 5 1/CD细胞培养液内均能检测到 5 FU。实验结果表明 :CD/5 FC系统可以用于胶质瘤的治疗 ,CD基因修饰U2 5 1细胞及其表达的离体研究为胶质瘤基因治疗的在体研究提供依据。     

Synthesis of 2-Tetrafluoroethyl-pseudooxazolone-(5)

The study describes the inhibitory activity of natural piericidins and related compounds, including synthetic analogues, to the electron transport system of mitochondria. Consideration of the structure-activity relationships led to the proposing of a structural unit I that was essential to inhibitory activity.     

Evaluation of ADA Gene Expression and Transduction Efficiency in ADA/SCID Patients Undergoing Gene Therapy

A capillary electrophoresis (CE) method was developed for ADA/SCID diagnosis and monitoring of enzyme replacement therapy, as well as for exploring the transfection efficiency for different retroviral vectors in gene therapy.     

Expression of the colH Gene Encoding Clostridium histolyticum Collagenase in Bacillus subtilis and Its Application to Enzyme Purification

The colH gene encoding 116-kDa collagenase of Clostridium histolyticum (cColH) was cloned into an Escherichia coli-Bacillus subtilis shuttle vector to develop a method for purification of recombinant collagenase (rColH). When plasmid pJCM310 containing the colH gene was introduced into B. subtilis DB104 and the transformant was grown in LB broth at 37 C, stability of the plasmid was not maintained. However, stability was partly improved by growing the transformant in a modified LB broth containing 0.5 M sodium succinate with gentle shaking at 35 C. When the transformant was grown to an optical density of 0.4 at 600 nm in this medium, pJCM310 was stable and rColH was produced in sufficient amounts. rColH was purified to homogeneity by ammonium sulfate precipitation, gel filtration and ion-exchange chromatography. The yield of rColH from an 800-ml culture was 0.53 mg and its specific activity was estimated to be 1,210 U per mg of protein. The purified rColH was capable of degrading native type-I collagen fibril from bovine achilles tendon, as was demonstrated by zymography. A comparison of the N-terminal amino acid sequence between cColH and rColH revealed that rColH has 10 extra N-terminal amino acid residues. However, the peptide mapping of rColH with V8 protease was virtually identical to that of cColH. Furthermore, the molecular mass of rColH was estimated to be 112,999 Da by mass spectrometry, coinciding with the value of 112,977 Da, which was predicted from the nucleotide sequence of the colH gene. Therefore, the recombinant B. subtilis culture is capable of serving as a useful source for enzyme purification.     

Antisense Oligodeoxynucleotides to the Cloned δ Receptor DOR-1: Uptake, Stability, and Regulation of Gene Expression

Abstract: Phosphodiester antisense oligodeoxynucleotides (ODNs) directed against various domains of the cloned mouse δ receptor DOR-1 reduce δ-opioid receptor binding in vivo and in vitro. The present study examines the stability of an antisense ODN (275 n M ) directed against the δ-opioid receptor and its effect on DOR-1 mRNA in cultured neuroblastoma cells and in vivo. When added to NG108-15 cells, much of the antisense ODN is degraded. However, >1% is intact, associated with cells, and stable for at least 72 h. Northern blot analysis demonstrates that treatment of NG108-15 cells with the antisense ODN reduces the levels of a species of DOR-1 mRNA by ∼25%. Similarly, intrathecal administration of the antisense ODN results in the accumulation of intact ODN within the spinal cord, which is stable for at least 72 h, although the levels of accumulation in vivo are lower than in vitro after either 4 or 72 h. Antisense ODN treatment lowers DOR-1 mRNA levels by ∼25%. The loss of mRNA both in vivo and in vitro corresponds quite well to the decreases in receptor binding previously observed by our laboratory and is consistent with reduction of δ-opioid receptor protein in vitro as determined by western blot with a monoclonal antibody selective for the δ-opioid receptor. In conclusion, these studies indicate that a small, but significant, proportion of ODN is taken up by cells and remains intact for up to 72 h. This appears to be sufficient to down-regulate mRNA levels of δ-opioid receptors and their expression.     

Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model

In a continuing study of our clinical candidate 5 VN/124-1 (TOK-001) and analogs as potential agents for prostate cancer therapy, putative metabolites (10, 15 and 18) of compound 5 were rationally designed and synthesized. However, none of these agents were as efficacious as 5 in several in vitro studies. Using western blot analysis, we have generated a preliminary structure–activity relationship (SAR) of 5 and related analogs as androgen receptor ablative agents (ARAAs). In vivo using the androgen-dependent LAPC-4 prostate cancer xenograft model, we demonstrated for the first time that 5 is more efficacious than the 17-lyase inhibitor 3 (abiraterone)/4 (abiraterone acetate) that is currently in phase III clinical trials. In our desire to optimize the potency of 5, compounds 6 (3ξ-fluoro-) and 9 (3β-sulfamate-) designed to increase the stability and oral bioavailability of 5, respectively were evaluated in vivo. We showed, that on equimolar basis, compound 6 was ∼2-fold more efficacious versus LAPC-4 xenografts than 5, but the toxicity observed with 6 is of concern. These studies further demonstrate the efficacy of 5 in a clinically relevant prostate cancer model and justify its current clinical development as a potential treatment of prostate cancer.